News headlines about Progenics Pharmaceuticals (NASDAQ:PGNX) have been trending positive this week, according to AlphaOne Sentiment Analysis. The research firm, a subsidiary of Accern, identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Progenics Pharmaceuticals earned a media sentiment score of 0.30 on AlphaOne’s scale. AlphaOne also gave headlines about the biotechnology company an impact score of 78 out of 100, indicating that recent press coverage is likely to have an impact on the company’s share price in the near term.
Shares of Progenics Pharmaceuticals (NASDAQ:PGNX) traded up 3.14% during midday trading on Monday, hitting $6.90. The stock had a trading volume of 1,281,918 shares. The firm has a market cap of $484.55 million, a price-to-earnings ratio of 71.13 and a beta of 3.37. Progenics Pharmaceuticals has a 12-month low of $4.00 and a 12-month high of $11.72. The company’s 50-day moving average price is $6.98 and its 200-day moving average price is $8.83.
Progenics Pharmaceuticals (NASDAQ:PGNX) last released its earnings results on Thursday, May 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by $0.07. The business had revenue of $2.40 million during the quarter, compared to analysts’ expectations of $4.50 million. Progenics Pharmaceuticals had a net margin of 10.24% and a return on equity of 7.50%. Progenics Pharmaceuticals’s revenue for the quarter was down 4.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.18) EPS. Equities research analysts forecast that Progenics Pharmaceuticals will post ($0.79) EPS for the current year.
A number of analysts have weighed in on PGNX shares. Zacks Investment Research cut Progenics Pharmaceuticals from a “buy” rating to a “sell” rating in a research report on Wednesday, May 10th. Needham & Company LLC reissued a “strong-buy” rating on shares of Progenics Pharmaceuticals in a report on Monday, April 24th. Jefferies Group LLC raised their price target on Progenics Pharmaceuticals from $13.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, April 4th. Finally, TheStreet cut Progenics Pharmaceuticals from a “c” rating to a “d+” rating in a report on Friday, May 26th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $10.96.
TRADEMARK VIOLATION WARNING: “Progenics Pharmaceuticals (PGNX) Receiving Positive Media Coverage, Report Shows” was originally reported by BBNS and is the sole property of of BBNS. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://baseballnewssource.com/markets/progenics-pharmaceuticals-pgnx-receives-daily-news-sentiment-rating-of-0-30-updated/985488.html.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.